Orchid Pharma Ltd
NSE:ORCHPHARMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 5-Year Average (1.3), the stock would be worth ₹-55.2 (109% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -14.4 | ₹612.85 |
0%
|
| 5-Year Average | 1.3 | ₹-55.2 |
-109%
|
| Industry Average | 47.3 | ₹-2 018.23 |
-429%
|
| Country Average | 35.9 | ₹-1 530.6 |
-350%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Orchid Pharma Ltd
NSE:ORCHPHARMA
|
31.1B INR | -14.4 | 164.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 140.4 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 35.1 | 27.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.4 | 20.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 24.8 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 43.2 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 21.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 11.6 | 16.4 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 20.7 |
| Median | 35.9 |
| 70th Percentile | 64.8 |
| Max | 50 585.9 |
Other Multiples
Orchid Pharma Ltd
Glance View
Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
